23.88
+0.1(+0.42%)
Currency In USD
| Previous Close | 23.78 |
| Open | 24.59 |
| Day High | 24.83 |
| Day Low | 23.66 |
| 52-Week High | 27.64 |
| 52-Week Low | 16.29 |
| Volume | 732,375 |
| Average Volume | 618,240 |
| Market Cap | 1.09B |
| PE | 50.81 |
| EPS | 0.47 |
| Moving Average 50 Days | 23.88 |
| Moving Average 200 Days | 24.5 |
| Change | 0.1 |
If you invested $1000 in Pacira BioSciences, Inc. (PCRX) 10 years ago, it would be worth $412.15 as of November 18, 2025 at a share price of $23.88. Whereas If you bought $1000 worth of Pacira BioSciences, Inc. (PCRX) shares 5 years ago, it would be worth $368.92 as of November 18, 2025 at a share price of $23.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nas
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
GlobeNewswire Inc.
Nov 04, 2025 12:00 PM GMT
-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin in 2026 -- BRISBANE, Calif., Nov. 04, 2025 (GLOBE
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will rep